Eyenovia, Inc. (NASDAQ: EYEN) (“Eyenovia” or the “Company”), an ophthalmic technology company developing and commercializing advanced products leveraging its proprietary Optejet topical ophthalmic medication dispensing platform, announces that it has entered into a non-binding letter of intent (LOI) contemplating a potential reverse merger transaction with Betaliq, Inc., a clinical stage pharmaceutical company with a therapeutic focus on glaucoma. The proposed merger would create a new ophthalmic company that combines two FDA-approved technologies: Betaliq’s EyeSol® water-free drug delivery technology for use in glaucoma, and Eyenovia’s Optejet topical ophthalmic liquid dispensing platform.
Read the full article: Eyenovia Enters into Non-Binding Letter of Intent to Effect Reverse Merger with Betaliq //
Source: https://www.globenewswire.com/news-release/2025/03/20/3046081/0/en/Eyenovia-Enters-into-Non-Binding-Letter-of-Intent-to-Effect-Reverse-Merger-with-Betaliq.html